Literature DB >> 20487259

PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection.

T Watanabe1, A Bertoletti, T A Tanoto.   

Abstract

Dysfunctional virus-specific T cells are a hallmark of many chronic viral infections. Recent studies have implicated the inhibitory PD-1/PD-L1 pathway with the functional impairment of T cells. In this respect, we will review the latest research on PD-1/PD-L1 pathway and T-cell exhaustion in the context of human chronic hepatitis B and C virus infections. We will also discuss the therapeutic potential of PD-1 blockade and how it may be enhanced through the modulation of other co-stimulatory/inhibitory pathways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20487259     DOI: 10.1111/j.1365-2893.2010.01313.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  52 in total

1.  Immunotherapy for lung cancer.

Authors:  María González-Cao
Journal:  Transl Lung Cancer Res       Date:  2015-12

2.  Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity.

Authors:  Jin-Young Choi; John Hsi-en Ho; Sandra G Pasoto; Viviane Bunin; Sang Taek Kim; Solange Carrasco; Eduardo F Borba; Celio R Gonçalves; Priscila R Costa; Esper G Kallas; Eloisa Bonfa; Joseph Craft
Journal:  Arthritis Rheumatol       Date:  2015-04       Impact factor: 10.995

3.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

Review 4.  Recent advances in the clinical development of immune checkpoint blockade therapy.

Authors:  Atefeh Ghahremanloo; Arash Soltani; Seyed Mohamad Sadegh Modaresi; Seyed Isaac Hashemy
Journal:  Cell Oncol (Dordr)       Date:  2019-06-14       Impact factor: 6.730

5.  Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils.

Authors:  Lauren A Licata; Cang T Nguyen; Rachel A Burga; Vincent Falanga; N Joseph Espat; Alfred Ayala; Mitchell Thorn; Richard P Junghans; Steven C Katz
Journal:  J Leukoc Biol       Date:  2013-07-24       Impact factor: 4.962

Review 6.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

7.  PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.

Authors:  Nikolaos Patsoukis; Duygu Sari; Vassiliki A Boussiotis
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

8.  B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function.

Authors:  Gang Cai; Xiaomeng Nie; Lei Li; Liang Hu; Beiying Wu; Jiafei Lin; Cen Jiang; Huaizhou Wang; Xuefeng Wang; Qian Shen
Journal:  J Gastroenterol       Date:  2013-03-27       Impact factor: 7.527

Review 9.  Biochemical signaling of PD-1 on T cells and its functional implications.

Authors:  Vassiliki A Boussiotis; Pranam Chatterjee; Lequn Li
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

10.  Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.

Authors:  Wen Yang; Yan Song; Yun-Long Lu; Jun-Zhong Sun; Hong-Wei Wang
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.